Background SLE is a complex autoimmune condition requiring evaluation across disease activity, permanent damage and ...

Objectives Pregnancy in SLE is associated with increased maternal and fetal risks but its impact on irreversible organ damage ...

Objective The Systemic Immune-Inflammation Index (SII) is an accessible haematological marker reflecting systemic ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Objective To assess real-world treatment regimens and patterns in childhood-onset SLE (cSLE) and adult-onset SLE (aSLE) cohorts, including similarities in treatments, duration of use and adherence.

Objective To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Conclusion In this real-world cohort, BEL treatment ...

Fertility is often a concern for women with SLE. In addition to known indirect factors that influence the ability of a woman with SLE to become pregnant, such as cytotoxic agents, other medications, ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Objectives Dysregulated IRF5 activity drives type I interferon, pathogenic cytokine production, and B cell activation and differentiation downstream of TLR7/8/9 signaling, contributing to systemic ...

Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective ...

22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...

Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...